A Prospective, Multicenter, Randomized, Blinded, Sham-controlled, Feasibility Study of Renal Denervation in Patients With Chronic Heart Failure

Chronic Heart Failure Clinical Trial

— RE-ADAPT-HF  

Official title:

A Prospective, Multicenter, Randomized, Blinded, Sham-controlled, Feasibility Study of Renal Denervation in Patients With Chronic Heart Failure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04947670
• Other study ID #: RE-ADAPT-HF (2021)
• Status: Recruiting
• Phase: N/A
• Start date: June 13, 2022
• Est. completion date: May 1, 2026

Study information

• Verified date: November 2022
• Source: Universität des Saarlandes
• Contact: Felix Mahfoud, MD
• Phone: +49-6841-16-15911
• Email: Felix.Mahfoud[@]uks.eu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The renin-angiotensin-aldosterone axis has been found to be a key system involved in heart failure disease progression and it may be inhibited by renal sympathetic denervation. Therefore, a clear need exists for further strategies to beneficially manipulate the sympathetic activation that is characteristic of the heart failure disease process.

The combined experience in the pilot studies and the EU randomized, controlled study indicates that the Paradise Catheter System can safely denervate renal sympathetic nerves of the kidney without significant periprocedural complications.

Preliminary results of a pilot study of catheter-based renal denervation in a small number of CHF patients did not show evidence of safety issues but suggest improvements in CHF symptoms. This trial will explore the safety and feasibility of renal denervation in a significantly higher number of patients with chronic heart failure. Both inter-individual and intra-individual controls will be used in order to obtain sufficient data and to in order to enable both treatment and control group to receive renal denervation.

Additionally, this feasibility trial to describe the safety and feasibility of renal denervation in patients with elevated sympathetic activity as in patients with chronic heart failure, will further the understanding of the role of renal nerves in the control of chronic heart failure and the pathogenesis of both ventricular remodeling and cardio-renal syndrome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 144
• Est. completion date: May 1, 2026
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient with CHF diagnosed for at least 3 months prior to consent

• 6-min walk distance =350 m

• NYHA Class II-III symptoms of CHF

• Systolic left ventricular dysfunction as assessed by echocardiogram with left ventricular ejection fraction <45%

• eGFR calculated (CKD-EPI) >30 ml/min/1.73 m2

• NT-pro-BNP >450 pg/ml, >900 pg/ml for patients with atrial fibrillation

• Optimal medical drug therapy according to current guidelines for CHF management. This medication may include loop diuretics, ACEi/ARBs, ARNI, SGLT-2 inhibitors, aldosterone antagonists, and beta-blockers, unless intolerance to any of the above is documented. Treatment for HF must be stable (including drug and dose) for 4 weeks prior to randomization, except diuretics (2 weeks stable)

• Appropriate use of medical devices such as an implantable cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international guidelines, and if a device is required, it must have been implanted for at least 3 months prior to consent for CRT and 1 month prior to consent for ICD

• Age =18 years and =80 years

Exclusion Criteria:

• Renal arterial anatomy that is ineligible for treatment

• Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 12 weeks prior to consent

• Office systolic BP at screening <90 mmHg

• Clinically significant cardiac structural valvular disease, unless corrected by a properly functional prosthetic valve

• Hypertrophic obstructive cardiomyopathy

• Major surgery in the previous 12 weeks prior to consent

• Hospitalization for decompensated CHF in the <30 days prior to consent

• Parenteral therapy for the treatment of CHF

• Respiratory support (excluding sleep apnea therapy)

• Left ventricular assist or planned heart transplantation

• Patient is pregnant, nursing, or planning to be pregnant

• Ineligibility to consent

• Primary pulmonary hypertension (systolic PAP >70 mmHg)

• BMI =40 kg/m²

• Any condition that would contraindicate the assessment of 6-min walk distance.

• Patient has type I diabetes mellitus

Related Conditions & MeSH terms

• Cardio-Renal Syndrome
• Chronic Heart Failure
• Heart Failure

Intervention

Procedure:
• Renal arteriography followed by renal denervation
Renal arteriography followed by renal denervation
• Sham Renal arteriography
Renal arteriography only

Locations

Country	Name	City	State
Germany	Saarland University Medical Center, Department for Internal Medicine III	Homburg/Saar	Saarland

Sponsors (2)

Lead Sponsor	Collaborator
Universität des Saarlandes	Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6 Minute Walk Test	Change in 6-min walk distance	6 months
Secondary	NT-proBNP	Change in plasma NT-proBNP values	6 months
Secondary	KCCQ	Change in Overall Summary Score measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)	6 months
Secondary	EQ-5D	Change in Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnea score	6 months
Secondary	eGFR	chronic eGFR slope defined as eCRF	6 months